T. S. Brown, R. J. McLaughlin, D. J. Berry, D. G. Lewallen, R. T. Trousdale, R. J. Sierra, Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Clin Orthop Relat Res. 2019 Feb;477(2):374-379. doi: 10.1097/CORR.0000000000000392.
Instability remains one of the most common indications for revision THA. However, little is known about the efficacy of surgery for and the complications associated with revision THA for patients with a chronically dislocated THA, which we define as a dislocation of more than 4 weeks.
QUESTIONS/PURPOSES: For patients with a chronically dislocated THA undergoing revision THA, we asked (1) What is the survivorship free from additional revision for these procedures? (2) What complications are associated with revision THA in this setting? (3) What are the clinical outcomes as measured by the Harris hip score in these procedures?
From 1998 to 2014, 1084 patients who underwent revision THA for instability were reviewed and 33 patients (33 hips) were identified who had a hip that had been dislocated for more than 4 weeks. Median time dislocated was 4 months (range, 1-120 months), and the mean distance of the femoral head above hip center at presentation was 45 mm. Mean patient age was 67 ± 17 years, and 79% of patients (26 of 33) were women. During the period in question, we used four approaches: Treatment with acetabular component revision in 18 of 33 patients (55%), head and liner exchange in nine patients (27%), both-component revision in five patients (15%), and isolated femoral component revision in one patient (3%). A constrained liner was used in 17 patients (52%), including six of the patients treated with acetabular component revision, and three of those who had both-component revisions. During the period in question, our general indications were hip pain and/or unacceptable function with the chronically dislocated prosthesis. Our sample size was too small to evaluate the association of the procedure choice on survivorship or complication risk. We used Kaplan-Meier survivorship analysis to estimate survivorship free from complication, reoperation, or revision. Mean followup was 4.4 years (range, 2-10 years).
Survivorship free from any revision, complication, or reoperation was 61% at 5 years (95% CI, 43-82). Survivorship free from revision was 83% at 5 years (95% CI, 67-98). Etiology for revision was aseptic loosening in three of 33 hips (9%), recurrent dislocation in two hips (6%), and deep periprosthetic joint infection in two hips (6%). Five complications (15%) did not result in a reoperation, including one dislocation and one incomplete peroneal nerve palsy in a patient after an anterolateral approach. The Harris hip score improved from mean 50 ± 17 preoperatively to mean 80 ± 11 at 5 years.
Chronically dislocated THAs can be successfully managed with revision THA. We recommend close evaluation of the components for aseptic loosening, performing revision surgery only on patients with pain and poor function, and thoroughly counseling patients that survivorship is modest and complications are common.
Level IV, therapeutic study.
不稳定仍然是翻修全髋关节置换术(THA)最常见的指征之一。然而,对于慢性髋关节脱位患者行翻修 THA 的疗效以及与翻修 THA 相关的并发症知之甚少,我们将慢性髋关节脱位定义为脱位超过 4 周。
问题/目的:对于慢性髋关节脱位接受翻修 THA 的患者,我们提出了以下三个问题:(1)这些手术的无额外翻修生存率是多少?(2)在这种情况下,翻修 THA 会出现哪些并发症?(3)这些手术的临床结果如何,用 Harris 髋关节评分来衡量?
1998 年至 2014 年,我们对 1084 例因不稳定而行翻修 THA 的患者进行了回顾性分析,其中 33 例(33 髋)髋关节脱位超过 4 周。中位脱位时间为 4 个月(范围,1-120 个月),就诊时股骨头距髋关节中心的平均距离为 45mm。平均患者年龄为 67±17 岁,79%(26/33)为女性。在研究期间,我们使用了四种方法:在 33 例患者中的 18 例(55%)采用髋臼组件翻修治疗,9 例(27%)采用股骨头和衬垫置换,5 例(15%)采用双组件翻修,1 例(3%)采用单纯股骨组件翻修。17 例(52%)使用了约束衬垫,包括 6 例接受髋臼组件翻修的患者和 3 例接受双组件翻修的患者。在研究期间,我们的一般适应证是慢性脱位假体引起的髋关节疼痛和/或功能无法接受。我们的样本量太小,无法评估手术选择对生存率或并发症风险的影响。我们使用 Kaplan-Meier 生存率分析来估计无并发症、再手术或翻修的生存率。平均随访时间为 4.4 年(范围,2-10 年)。
5 年时无任何翻修、并发症或再手术的生存率为 61%(95%CI,43%-82%)。5 年时无翻修生存率为 83%(95%CI,67%-98%)。翻修的病因包括 33 髋中的 3 髋(9%)为无菌性松动,2 髋(6%)为复发性脱位,2 髋(6%)为深部假体周围关节感染。有 5 例(15%)并发症未进行再手术,包括 1 例前外侧入路患者发生脱位和 1 例不完全腓总神经麻痹。Harris 髋关节评分从术前的 50±17 提高到 5 年时的 80±11。
慢性髋关节脱位可以通过翻修 THA 成功治疗。我们建议仔细评估组件的无菌性松动情况,仅对有疼痛和功能不佳的患者进行翻修手术,并向患者充分说明生存率较低且并发症较为常见。
IV 级,治疗性研究。